《半日速报》恒指半日收报26,481点 升21点; 恒生科技指数半日收报8,221点 升75点 中生制药升逾5% 药明生物(新)、洛阳钼业、再鼎医药创新高
恒指半日收26,481点,升21点或0.1%。恒生科技指数报8,221点,升75点或0.9%。国指升28点或0.3%,报10,490点。
活跃重磅股表现:
阿里巴巴(09988.HK) 收256.2元,上升2.1%;
友邦(01299.HK) 收89.6元,下跌1.5%;
美团(03690.HK) 收283.2元,上升1.4%;
腾讯(00700.HK) 收576.5元,上升0.9%;
平安(02318.HK) 收94.45元,上升0.8%;
建行(00939.HK) 收5.71元,下跌0.7%;
异动恒指及国指成份股:
中生制药(01177.HK) 收7.72元,上升5.9%;
百威亚太(01876.HK) 收25.65元,下跌5%;
药明生物(新)(02269.HK) 收85.9元,上升4.8%,创新高;
安踏(02020.HK) 收107元,下跌4.5%;
网易(09999.HK) 收140.5元,上升4.1%;
石药(01093.HK) 收8.08元,上升4%;
恒安(01044.HK) 收54.9元,上升3.6%;
京东集团(09618.HK) 收322.2元,上升3.4%;
异动综合中小型股:
康基医疗(09997.HK) 收15.76元,上升19.6%;
亚盛医药(06855.HK) 收33.9元,上升10.4%;
洛阳钼业(03993.HK) 收4.2元,上升5.5%,创新高;
再鼎医药(09688.HK) 收918.5元,上升4.3%,创新高;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.